Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald P Radich

Showing results (191-200 of 208) with videos related to

Pageof 21
Sort By:
Ejhaem|December 18, 2024
Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG reportJasmine Naru, Megan Othus, ChenWei Lin, et al.
Blood|August 30, 2011
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOGPhoenix A Ho, Kenneth J Kopecky, Todd A Alonzo, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJerald P Radich, Michael Deininger, Camille N Abboud, et al.
Bone Marrow Transplantation|November 25, 2025
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemiaRasha W Al-Ali, Gege Gui, Niveditha Ravindra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Arnel Pallera, Jessica K Altman, Ellin Berman, et al.
Blood|November 15, 2021
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosisHelong Zhao, Anthony D Pomicter, Anna M Eiring, et al.
Blood Advances|June 2, 2023
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysisSara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, et al.
The New England Journal of Medicine|December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker, François Guilhot, Stephen G O'Brien, et al.
Blood|June 28, 2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Michele Baccarani, Michael W Deininger, Gianantonio Rosti, et al.
Pageof 21

Showing results (191-200 of 208) with videos related to

Sort By:
Pageof 21
Ejhaem|December 18, 2024
Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG reportJasmine Naru, Megan Othus, ChenWei Lin, et al.
Blood|August 30, 2011
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOGPhoenix A Ho, Kenneth J Kopecky, Todd A Alonzo, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJerald P Radich, Michael Deininger, Camille N Abboud, et al.
Bone Marrow Transplantation|November 25, 2025
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemiaRasha W Al-Ali, Gege Gui, Niveditha Ravindra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Arnel Pallera, Jessica K Altman, Ellin Berman, et al.
Blood|November 15, 2021
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosisHelong Zhao, Anthony D Pomicter, Anna M Eiring, et al.
Blood Advances|June 2, 2023
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysisSara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, et al.
The New England Journal of Medicine|December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker, François Guilhot, Stephen G O'Brien, et al.
Blood|June 28, 2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Michele Baccarani, Michael W Deininger, Gianantonio Rosti, et al.
Pageof 21